Search results
This article is the second in a 2-part series discussing the diagnosis and management of immune-mediated hemolytic anemia in dogs and cats. The authors provide an overview of diagnostics and describe the therapeutic approaches for treating the disorder.
Immune-mediated hemolytic anemia is one of the most common immune-mediated hematologic disorders in dogs and cats. Part 1 of this 2-article series discusses pathophysiology and diagnosis of IMHA, including patient predilection, history and clinical signs, physical examination, diagnostics, and differential diagnoses.
23 paź 2023 · Proving the condition is immune-mediated and includes hemolysis is more challenging. Evidence of immune-mediated destruction includes a positive saline slide agglutination test (SAT), direct Coomb’s test, spherocytosis (in dogs), and flow cytometry.
No difference in recovery of acid/base and perfusion variables was found, but those dogs receiving pRBC had a faster clinical recovery. 39 In conclusion, BHS could be administered if pRBC or whole blood are not available.
2 wrz 2021 · Immune-mediated haemolytic anaemia (IMHA) is one of the most prevalent immune-mediated diseases in canines, and it carries a guarded prognosis because of the substantial rates of morbidity and mortality. Comprehensive supportive nursing care is critical in patients with IMHA.
1 sie 2019 · Median survival time was 913 days for all dogs. CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that most dogs with PIMA responded to prolonged immunosuppressive therapy. Studies to determine optimal immunosuppressive and thromboprophylactic protocols for dogs with PIMA are warranted.
13 paź 2021 · A 2019 ACVIM consensus statement on diagnostics for immune-mediated hemolytic anemia (IMHA) in dogs made testing recommendations. As data on the performance of immunohematological tests was lacking, we undertook a comparative analysis.
